Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability.
about
Identification of novel imidazo[1,2-a]pyridine inhibitors targeting M. tuberculosis QcrBIdentification of potent inhibitors of the chicken soluble epoxide hydrolase.Antimicrobial and hypoglycemic activities of novel N-Mannich bases derived from 5-(1-adamantyl)-4-substituted-1,2,4-triazoline-3-thionesExplorations of substituted urea functionality for the discovery of new activators of the heme-regulated inhibitor kinaseThe tuberculosis drug discovery and development pipeline and emerging drug targets.A Nano-MgO and Ionic Liquid-Catalyzed 'Green' Synthesis Protocol for the Development of Adamantyl-Imidazolo-Thiadiazoles as Anti-Tuberculosis Agents Targeting Sterol 14α-Demethylase (CYP51).New approaches to target the mycolic acid biosynthesis pathway for the development of tuberculosis therapeutics.The Mycobacterium tuberculosis secreted protein Rv0203 transfers heme to membrane proteins MmpL3 and MmpL11.Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3-heteroaryl ureas with improved in vitro pharmacokinetic properties.Insights on how the Mycobacterium tuberculosis heme uptake pathway can be used as a drug target.Progress in targeting cell envelope biogenesis in Mycobacterium tuberculosis.Recycling and refurbishing old antitubercular drugs: the encouraging case of inhibitors of mycolic acid biosynthesis.Resistance in tuberculosis: what do we know and where can we go?Novel diagnostics and therapeutics for drug-resistant tuberculosis.Tuberculosis drug discovery and emerging targets.Iron Acquisition Mechanisms: Promising Target Against Mycobacterium tuberculosisDesign, synthesis and evaluation of indole-2-carboxamides with pan anti-mycobacterial activity.New structural classes of antituberculosis agents.Solvent-free synthesis, DNA-topoisomerase II activity and molecular docking study of new asymmetrically N,N'-substituted ureas.HC2091 kills Mycobacterium tuberculosis by targeting the MmpL3 mycolic acid transporter.Synthesis, Antimicrobial and Hypoglycemic Activities of Novel N-(1-Adamantyl)carbothioamide Derivatives.
P2860
Q28484670-2713D647-F7F8-47F1-BE68-00C6911FDA06Q34778159-ABF8259A-11F7-4A83-89B4-74F6DC25EEE2Q34835155-73FC6B7E-3086-494C-9B9D-B56CC5DCDF9FQ35049870-290A9439-58AE-4A80-B655-158D9BA15804Q35664209-1A4DB741-4427-4EBB-9DFC-ABDAD89914B2Q35808907-9558445A-7E77-4B39-A2F7-8793CBF02392Q36057012-8F018336-A01D-4EA5-9994-69439D0908C3Q37048385-4C5F3AD8-83F2-4C1B-A8D8-599D2A617257Q37190451-0C145C97-158F-414F-9571-F16C971A2DADQ37337116-670B3FB9-7F3B-4FB5-B4C5-9BA136059639Q37403156-081F3423-E040-45D0-A41B-4400048DDC47Q38097123-0C07F112-BD3B-4C0E-96BB-2AC2E2E710CEQ38124261-99D48A08-8575-4982-BBD4-F2B8223C4D5DQ38210363-CBC5A120-F599-4F67-8B47-F928D5BEA516Q38219605-8BF64F32-06B1-4710-B997-C315E687FEBEQ38606667-ECD574D1-35E4-42AA-B15B-1CE2C9D1DE7FQ38702237-491B5301-47E2-4322-8BC0-C75F395B9945Q39362128-CE7FE831-6664-4FC4-9D3D-2D5D149745C3Q50488437-72F1B0E3-330D-4785-936F-F750A699B437Q52584718-F6B0E64F-C657-430D-B92D-3C51EE7EA55FQ53800929-4E752D11-7484-4715-907D-4859288BE514
P2860
Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Screening a library of 1600 ad ...... roperties for bioavailability.
@ast
Screening a library of 1600 ad ...... roperties for bioavailability.
@en
Screening a library of 1600 ad ...... roperties for bioavailability.
@nl
type
label
Screening a library of 1600 ad ...... roperties for bioavailability.
@ast
Screening a library of 1600 ad ...... roperties for bioavailability.
@en
Screening a library of 1600 ad ...... roperties for bioavailability.
@nl
prefLabel
Screening a library of 1600 ad ...... roperties for bioavailability.
@ast
Screening a library of 1600 ad ...... roperties for bioavailability.
@en
Screening a library of 1600 ad ...... roperties for bioavailability.
@nl
P2093
P2860
P1476
Screening a library of 1600 ad ...... roperties for bioavailability.
@en
P2093
Anna E Grzegorzewicz
Anne J Lenaerts
Christophe Morisseau
Elton J North
In-Hae Kim
Michael R McNeil
Michael S Scherman
Oleg Merzlikin
Takeo Kasagami
Tamara N Hess
P2860
P304
P356
10.1016/J.BMC.2012.03.058
P407
P577
2012-03-31T00:00:00Z